Popular anti-diabetes and obesity drug Mounjaro has been launched in India, by the US-based pharmaceutical giant Eli Lilly, ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & CompanyTwo lead programs in ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Walmart, Eli Lilly and Company, Intuitive Surgical, UnitedHealth Group, and Abbott Laboratories are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...